Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
October 16, 2019
Vyleesi™ Phase 3 Data To Be Presented At The 13th European Society Of Gynecology Congress
CRANBURY, N.J., Oct. 16, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) announced today that data from two pivotal, double-blind placebo-controlled Phase 3 trials ...
October 16, 2019
Armata Pharmaceuticals Strengthens Clinical Team with Appointment of Dr. Heather Dale Jones as Medical Director
MARINA DEL REY, Calif., Oct. 16, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage ...
October 16, 2019
Beyond Air™ Provides Update on High Concentration Nitric Oxide (NO) Animal Studies Using LungFit™
GARDEN CITY, N.Y. and REHOVOT, Israel, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused ...
October 16, 2019
RedHill Biopharma Sponsors No Stomach For Cancer’s Symposium Ahead of Stomach Cancer Awareness Month
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 16, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a ...
October 16, 2019
Bionano Genomics Announces Adoption of Its Saphyr® System by Clinical Cytogenetics Groups in Academia and Industry to Replace Traditional Methods for Clinical Testing
SAN DIEGO, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), a life sciences instrumentation company that develops and markets the Saphyr® system, a ...
October 16, 2019
CorMedix Completes Successful CMC Interaction with the FDA
BERKELEY HEIGHTS, N.J., Oct. 16, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for ...
October 16, 2019
Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent
WATERTOWN, Mass., Oct. 16, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, today announced that the ...
October 15, 2019
Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression
NEW YORK, Oct. 15, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) ...
October 15, 2019
HTG Announces the Launch of its New Autoimmune Profiling Assay
TUCSON, Ariz., Oct. 15, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today ...
October 15, 2019
Cue Biopharma to Present at the Oppenheimer Houston Oncology Summit at the University of Texas MD Anderson Cancer Center
CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively ...
October 15, 2019
Cellectar Presents Poster at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology
FLORHAM PARK, N.J., Oct. 15, 2019 (GLOBE NEWSWIRE) --  Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs ...
October 15, 2019
OncoCyte to Present Data From a Study Examining Its Liquid Biopsy Test During the CHEST Annual Meeting 2019
ALAMEDA, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a molecular diagnostics company providing actionable answers at critical decision points across ...
October 15, 2019
Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma
SYDNEY, Australia, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments ...
October 15, 2019
CohBar to Present at the 2019 BIO Investor Forum
MENLO PARK, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases ...
October 15, 2019
Abeona Therapeutics Announces Publication of Positive Long-Term Data from Phase 1/2a Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
NEW YORK and CLEVELAND, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced positive ...
October 15, 2019
Onxeo to Present Final Results of DRIIV-1 Phase 1 Study of AsiDNA™ in Advanced Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Onxeo S.A. (ONXEO.PA) (NASDAQ OMX:ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response ...
October 14, 2019
Lipocine to Present at the B. Riley NASH Symposium
SALT LAKE CITY, Oct. 14, 2019 /PRNewswire/ -- Lipocine Inc. (LPCN), clinical-stage biopharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will participate in ...
October 14, 2019
Salarius Pharmaceuticals to Present at Two Upcoming Investor Conferences
HOUSTON, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced its ...
October 14, 2019
CymaBay Therapeutics to Present at the H.C. Wainwright 3rd Annual NASH Investor Conference
NEWARK, Calif., Oct. 14, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies ...
October 14, 2019
Pfenex Reports Positive Results for PF708 Comparative Use Human Factors Study
SAN DIEGO, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today it has successfully completed the PF708 comparative use human factors ...
Page 2 of 169